Valuation : InspireMD

Market Cap 3.97Cr 3.41Cr 3.21Cr 2.93Cr 5.48Cr 375.12Cr 5.5Cr 38Cr 15Cr 192.1Cr 15Cr 15Cr 611.9Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 3.97Cr 3.41Cr 3.21Cr 2.93Cr 5.48Cr 375.12Cr 5.5Cr 38Cr 15Cr 192.1Cr 15Cr 15Cr 611.9Cr EV / Sales 2026 *
4.05x
EV / Sales 2027 * 1.97x
Free-Float
80.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/01/2020
Director of Finance/CFO 58 25/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 71 02/06/2017
Director/Board Member 68 07/02/2013
Director/Board Member 62 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%+32.01% - - 3.97Cr
-1.58%-8.33%-22.73%+4.85% 12TCr
0.00%+0.14%-24.86%+1.96% 1.21TCr
-1.60%-1.33%+88.92%+131.23% 1.05TCr
-0.58%-1.20%-51.29%-71.01% 419.79Cr
-0.97%-9.65%-24.95%+35.52% 248.28Cr
-0.54%-5.73% - - 194.04Cr
+1.51%+2.67%-27.04%-73.72% 182.37Cr
-0.31%-4.00%-18.72%-24.58% 156.74Cr
Average -0.95%-1.95%-11.52%+0.61% 1.89TCr
Weighted average by Cap. -1.40%-6.60%-15.91%+10.60%

Financials

2026 *2027 *
Net sales 97.99L 84.27L 79.26L 72.36L 1.35Cr 93Cr 1.36Cr 9.4Cr 3.63Cr 47Cr 3.68Cr 3.6Cr 151.17Cr 2.01Cr 1.73Cr 1.63Cr 1.49Cr 2.78Cr 190.4Cr 2.79Cr 19Cr 7.46Cr 98Cr 7.56Cr 7.4Cr 310.57Cr
Net income - -
Net Debt - -
Logo InspireMD
InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!